A woman in her forties came to the counter with her Wegovy refill and a question she had clearly been carrying for a while. "My sister stopped hers after a year and put back every pound she lost. Do I have to take this forever?" The scene is a composite of several conversations, but the question comes up often.

Whether you stop is a decision for you and your prescriber, not something to settle on your own. Still, the question "what happens?" deserves a straight answer. Many people assume the weight stays off once the injections end. In the trial that looked most closely at stopping, it largely did not.

What the STEP 4 trial found

STEP 4, published in JAMA in 2021, followed adults with overweight or obesity who did not have diabetes. Everyone first took weekly semaglutide 2.4 mg (the Wegovy dose) for 20 weeks. The 803 people who reached that dose were then randomly assigned either to keep taking semaglutide or to switch to placebo, and they were followed up to week 68. Between weeks 20 and 68, average weight changed by -7.9% in the group that kept semaglutide and by +6.9% in the group that switched to placebo, a difference of 14.8 percentage points.

In plain terms, people who continued kept losing weight, while people who switched gained some of it back. Averages hide a wide range, so your own pattern could be faster or slower. The direction is clear, though, and it matches what many people tell me at the counter.

The trial also has limits. It followed people for 68 weeks, which is shorter than some people will take these medicines. It tested the weight loss dose in people without diabetes, so it does not tell us exactly what happens when someone with type 2 diabetes stops Ozempic. Its participants were enrolled and followed under research rules, so people in everyday life, with other health conditions and other medicines, may not match the average. Treat it as a guide to what usually happens, not a forecast for your body.

Why the weight tends to come back

These medicines work largely on the signals that control appetite and fullness. While you take them, hunger is quieter and portions feel smaller. When they stop, those signals return to their earlier pattern, and so can the eating habits that came with them. That is a biological response to a change in treatment, not a character flaw.

Stopping is a plan, not an event

The NHS advice on semaglutide is simple: keep taking your medicine unless you are advised to stop, talk to your doctor before stopping, and do not stop suddenly. It adds that your doctor may suggest reducing the dose gradually. That advice protects you from stopping because a friend did, or because the nausea finally settled, or because the price jumped one month. Each of those is a reason to call your prescriber, not a reason to skip doses. Waiting until a crisis forces the decision usually leads to a rushed plan, so it is better to raise the question at a routine review, while you are still feeling steady.

When you do talk it through, these questions help:

Is stopping the right next step for me, or would a gentler plan work better?
What should I watch for in the weeks after my last injection?
If I take insulin or other diabetes tablets, do those doses need a review?
What will my plan be for meals, protein and daily activity?
If my weight or blood sugar moves in the wrong direction, what is the plan?

On the blood sugar point, readings can shift when the injections stop. If you take insulin or other diabetes medicines, ask whether they need a check. The American Diabetes Association Standards of Care in Diabetes 2026 give a before-meal goal of 80 to 130 mg/dL (4.4 to 7.2 mmol/L) and a peak after-meal goal below 180 mg/dL (10.0 mmol/L) for many nonpregnant adults. Your own targets are set by your care team, so use theirs.

A practical plan for the first weeks

Whatever you decide with your prescriber, a few steps make the transition easier:

Weigh yourself once a week, at the same time and in the same way, and write the number down with a note about your appetite.
Keep a simple food and drink log for two weeks. You are looking for patterns, not perfection.
Plan some protein at each meal, and keep easy options in the house, such as eggs, beans, fish, yogurt or chicken.
Schedule short walks or other movement you enjoy, and add some strength work if you can manage it.
Book your follow-up before your last injection, not after, so there is no gap in support.
Tell your prescriber or diabetes team if you notice more thirst, passing more urine or tiredness, because these can signal a change in blood sugar.

If side effects are the reason

Side effects are one of the most common reasons people want to stop. Before you decide, ask whether they can be eased. The NHS says to speak to a pharmacist or doctor if side effects bother you or do not go away, and that they can suggest ways to reduce them. Smaller meals, slower eating and steady fluids are often part of that talk. Any change to the dose schedule belongs to your prescriber.

If cost or supply is the reason

Cost is a real barrier, and it is better to raise it early than to run out. Ask your prescriber or pharmacist what options exist where you live and what your plan covers. Please do not fill a gap with compounded or "research" products, unlabeled pens, or online sellers that do not ask for a prescription. The FDA warns that compounded and unapproved versions of semaglutide and tirzepatide have not been reviewed for safety, effectiveness or quality, and that some online sellers supply counterfeit or mislabeled products. The safest route is a prescription from a licensed clinician, filled at a licensed pharmacy.

Keeping what you have built

Whether or not you continue, the habits that helped are worth keeping: regular meals with protein, plenty of vegetables, drinks without added sugar, and movement you enjoy. Strength training helps protect muscle while your weight changes. Ask your pharmacist for a simple plan to follow once the injections stop, so you know what to do in the first week instead of waiting to see what the scales say.

Questions to ask your doctor or pharmacist

Is stopping the right next step for me, or is there a gentler option?
What weight and appetite changes should I expect, and when do you want to see me?
Do my insulin or diabetes tablets need changing if I stop?
What should I eat, and how active should I be, in the first three months after stopping?
If I stop and feel worse, what is the plan, and how would I restart safely?
Which warning signs should make me call you the same day?

Frequently asked questions

Will the weight definitely come back?

Not for everyone, and not by the same amount. The trial results are averages. In STEP 4, the people who switched to placebo regained weight on average, while the people who kept semaglutide kept losing. Your own pattern depends on your food, activity, sleep, stress and other health conditions.

Is it safe to take a break?

Only with a plan from your prescriber. A break is a change to treatment, and the right timing and monitoring depend on your health and your other medicines.

Can I restart later?

Possibly, but restarting is a prescriber decision. The right dose depends on how long you have been off the medicine. The current Wegovy label says that if 2 or more doses in a row are missed, the dose increases should be started again at a lower dose, which helps reduce stomach side effects. So do not restart from an old pen or a leftover supply without advice.

Does stopping mean I failed?

No. Weight is shaped by appetite, sleep, stress, medicines and biology, not only by effort. Stopping is a point to plan around, not a verdict on you.

If you'd like the full guide, my book The Pharmacist's GLP-1 Guide goes deeper into starting these medicines safely, managing side effects and keeping the weight off.

Sources

NHS Medicines Resources. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial
Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021. doi:10.1001/jama.2021.3224
NHS. Semaglutide
NHS. Acute pancreatitis
DailyMed. WEGOVY (semaglutide) injection and tablets prescribing information, revised 06/2026
U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated October 1, 2026)
American Diabetes Association Professional Practice Committee. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes 2026. Diabetes Care. 2026;49(Suppl 1):S132-S149.